Geron Corporation (NASDAQ: GERN) is making a run for the top in the market this morning, and for good reason. The company announced that data from its IMbark Phase 2 clinical trial was featured in the Journal of Clinical Oncology. Here’s what’s going on: Stop wasting your time! Start finding winning trades in minutes with … Read more
Geron Corporation (NASDAQ: GERN) is having an overwhelmingly rough start to the trading session this morning, and for good reason. The company announced that a Collaboration and License Agreement (CLA) has been terminated, upsetting investors and sending the stock tumbling down. Today, we’ll talk about: The news; what we’re seeing from GERN as a result; … Read more
Geron Corporation (NASDAQ: GERN) is headed for the top in the market today as investor excitement ensues surrounding a coming earnings release. In a press release issued early this morning, the company announced that it will release its earnings and hold its 2018 Annual Meeting of Stockholders relatively soon. Today, we’ll talk about: The announcement; … Read more
Geron Corporation (NASDAQ: GERN) has been a hot topic among biotechnology investors for some time now, and for good reason. Recently, investors have been paying attention to the overall survival rate data that was released from the IMbark clinical trial, which is admittedly impressive. This has led to a dramatic run that the stock remains … Read more
Geron Corporation (NASDAQ: GERN) Geron Corporation is having an incredibly strong start to the trading session this morning, and for good reason. The company provided an update with regard to key clinical trials. As a result, investor excitement ensued, leading to gains and prompting our partners at Trade Ideas to alert us to the movement. At … Read more
It seems as though the bears are taking over the BioTech space today following a relatively strong week for many in the industry. Today, we’ll take a look at Orexigen (OREX), Geron Corporation (GERN), Genetic Technologies (GENE), MannKind (MNKD), and Galena Biopharma (GALE). So, let’s get right to it. Orexigen (OREX) Stocks Still Struggling As … Read more